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COPD; chronic obstructive pulmonary disease, HTN; hypertension, GI gastrointestinal.
Disclosures. All authors:
No reported disclosures. Background. Mycobacterium immunogenum is a somewhat recently identified species of rapidly growing nontuberculous mycobacteria, genetically related to M. abscessus and M. chelonae. Resistance patterns of rapidly growing nontuberculous mycobacterium species can make them difficult to treat. This is particularly true of M. immunogenum, in part due to the infrequency of reported cases of human infection and limited data to guide therapy.
Treatment of Mycobacterium immunogenum
Methods. We present here a case of M. immunogenum skin and soft-tissue infection at the site of insertion of a peritoneal dialysis catheter in a patient with end-stage renal disease. He initially presented with nodular subcutaneous lesions around his catheter site that progressed through oral antibiotics. This led to sampling which confirmed the diagnosis of M. immunogenum. We conducted a review of the literature to identify previously reported cases of M. immunogenum, including skin and soft-tissue infections, and used these data to guide management.
Results. We reviewed 11 reports (cases and case series) of Mycobacterium immunogenum in the literature. Susceptibilities often take weeks to return, and so empiric therapy is based on case series, and then later adjusted based on susceptibilities. Patients received combined antimicrobial regimens with durations of 2 weeks to 12 months, with variable outcomes. Several required surgical debridement, as was the case with our patient. His PD catheter was removed and he was treated empirically with amikacin, azithromycin, and tigecycline intravenous induction. His ultimate long-term regimen was later switched to azithromycin, clofazimine, and tedizolid due to side effects and the eventually available susceptibility profile.
Conclusion. The treatment of M. immunogenum remains a challenge due to the relative scarcity of data to guide treatment, and consequent lack of systemic approach to therapy. Most reported cases involve the use of a macrolide, often in combination with an aminoglycoside or a fluoroquinolone. Several started with intravenous induction, followed by transition to oral therapy on the order of weeks to months. Others also require surgical debridement. More data are required to develop a standardized approach to the treatment of M. immunogenum.
Disclosures. All authors: No reported disclosures. Background. Mycobacterium abscessus harbors a β-lactamase enzyme, Bla Mab , able to hydrolyze penicillins, most cephalosporins and carbapenems. As of today, management of M. abscessus with β-lactams does not include combination of β-lactamase inhibitors. The potential benefit of combinations of several β-lactams with new diazabicyclooctane (DBO) inhibitors, such as relebactam and avibactam, has not been well studied. Based upon the ability to inhibit BlaMab by highly potent DBO inhibitors, our goal herein was to investigate the efficacy of a novel combination, ceftaroline (CEF) and avibactam (AVI), to restore susceptibility to β-lactam antibiotics and inhibit growth.
Ceftaroline and Avibactam? Is This a Potential Combination for
Methods. Minimum inhibitory concentrations (MICs) of CEF with or without AVI were examined using the microdilution method.
Results. MIC 50 and MIC 90 of CEF is 8 mg/L; in the presence of 4 μg/mL of AVI, the MICs of CEF decreased to ≤4 mg/L in 31 of 35 cases (table) .
Conclusion. Our results add to the growing evidence of using β-lactams as agents effective against Mycobacterial infections. Inhibition of the hydrolytic activity of (BlaMab) using DBOs such as AVI suggest that this combination should be evaluated in animal and clinical models. Background. Mycobacterium abscessus is an emerging multi-drug-resistant pathogen, harboring the β-lactamse Bla MAB . Avibactam is a non-β-lactam, β-lactamase inhibitor shown to inhibit Bla MAB and improve the efficacy of ampicillin for M. abscessus infections in in vitro and in vivo models. Whether the addition of avibactam to piperacillin enables use of the latter against M. abscessus is unknown Methods. We used a recombinant, luminescent M. abscessus to measure the reduction of MIC to meropenem, ampicillin, and piperacillin induced by avibactam. We then used our previously established G. mellonella infection model (Figure 1) 1 to evaluate the effect of antimicrobial treatments in vivo.
Results. Addition of avibactam (4 µg/mL) consistently decreased MIC of ampicillin and piperacillin by 16 and 16-32-fold, respectively, but as expected had no significant effect on meropenem MIC (Figure 2) . We inoculated 60 G. mellonella larvae with luminescent M. abscessus on day 0, and treated larvae with meropenem, piperacillin, avibactam alone, or piperacillin combined with avibactam on days 2 and 3. Using IVIS ® imaging, we measured infection progression in live infected larvae on day 4. Larvae treated with meropenem and piperacillin-avibactam had significantly lower infection burden compared with untreated controls (P < 0.0001 and P = 0.004, respectively). Piperacillin and avibactam alone had no significant inhibitory effect (Figure 3) Background. Pyrazinamide (PZA) is a key drug for both drug-sensitive and drug-resistant tuberculosis (TB). Patients co-infected with TB and human immunodeficiency virus (HIV) are more likely to have low blood levels of PZA, associated with inferior outcomes. Therapeutic drug monitoring (TDM) with sparse blood sampling is recommended for high-risk groups, including HIV/TB patients, but the accuracy is uncertain. We performed a pharmacokinetic (PK) simulation study to estimate the diagnostic accuracy of TDM for PZA among HIV/TB patients.
Methods. We recently performed a population PK study among HIV/TB patients in Botswana, identifying a 1-compartment model with first-order elimination. In the current work, we performed an intensive PK simulation (n = 10,000 patients) to determine the accuracy of sparse blood sampling in identifying HIV/ TB patients with low PZA blood levels, as defined by the AUC in a dosing interval (AUC 0-24 ) predictive of successful outcome (363 mg*hr/L). PZA dosing followed WHO guidelines with weight-based dosing bands. In secondary analysis, we examined the peak concentration (Cma x ) target predictive of 2-month sputum conversion (58 mg/L). To determine the accuracy of sparse sampling (2-and 6-hours), we performed receiver-operating-characteristic (ROC) analysis, with bootstrapping (n = 1,000) for 95% confidence intervals (CI), and defined accuracy as the area under the ROC curve.
Results. In this simulation PK study of PZA among HIV/TB patients, the PZA AUC 0-24 fell below the target in 29% of patients, while in 71% of patients the PZA C max was below the target. For the AUC 0-24 target, the area under the ROC curve was 0.69 (95% CI 0.68-0.70) for a single 2-hour sample, increasing to 0.75 (95% CI 0.74-0.76) for 2-and 6-hour samples. For the C max target, diagnostic accuracy was similar for a 2-hour sample (0.87, 95% CI 0.86-0.87) and 2-and 6-hour samples (0.88, 95% CI 0.88-0.89).
Conclusion. We observed modest diagnostic accuracy of TDM for identifying in silico HIV/TB patients with low PZA AUC 0-24 , and higher accuracy for low C max . By identifying diagnostic performance characteristics of sparse sampling strategies, including optimal cut-offs, the ROC framework can support wider implementation of TDM in high-risk TB populations.
